Rockville, Maryland, United States – September 7, 2026 – New treatment options are reshaping the management of connective tissue disease-associated interstitial lung disease (CTD-ILD), but significant unmet need remains. A June 2026 physician survey found that only 15% of CTD-ILD patients were estimated to achieve drug-free remission, while rheumatologists and pulmonologists continued to identify better efficacy, fibrosis reversal, tolerability, and disease-specific therapies as major priorities.

Against this backdrop, Fact.MR estimates that the global connective tissue disease market will grow from USD 29.8 billion in 2026 to USD 48.5 billion by 2036, expanding at a 5.0% CAGR. The market reached USD 28.4 billion in 2025, creating an estimated absolute opportunity of USD 18.7 billion through 2036.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15832

Why Connective Tissue Disease Treatment Is Expanding

Connective tissue diseases cover a broad group of autoimmune and inflammatory disorders affecting joints, skin, blood vessels, muscles, and internal organs. Rheumatoid arthritis and systemic lupus erythematosus remain major treatment categories, while systemic sclerosis, Sjögren's syndrome, and mixed connective tissue disease add further demand for specialist care.

Earlier disease control is becoming increasingly important. Persistent inflammation can contribute to irreversible joint or organ damage, encouraging physicians to reassess treatment when conventional therapies do not provide adequate control.

Fact.MR identifies early disease control and switching demand as the leading growth driver, with an estimated +1.4% impact on CAGR. Biologic and targeted therapy use contributes another +1.1%, while hospital-led infusion and monitoring adds +0.9%.

Rheumatoid Arthritis Remains the Largest Disease Segment

Rheumatoid arthritis is projected to account for 36.0% of the market in 2026, making it the leading disease type covered by Fact.MR.

The disease's established treatment pathways and recurring need for disease-modifying therapy create a substantial commercial base. Patients may require long-term monitoring, treatment adjustments, and response assessments as disease activity changes.

The market is not limited to rheumatoid arthritis. Fact.MR's scope also includes systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, and mixed connective tissue disease.

The breadth of these conditions is commercially relevant because treatment decisions increasingly depend on disease severity, organ involvement, previous treatment response, and patient-specific safety considerations.

Biologics Lead Treatment Demand

Biologics are expected to represent 34.0% of the treatment-type segment in 2026.

Targeted biologics can provide physicians with defined immune pathways when conventional disease-modifying antirheumatic drugs do not deliver sufficient disease control or cannot be tolerated. TNF inhibitors and interleukin inhibitors remain important components of this treatment landscape.

The competitive environment is also changing as biosimilars create additional options around established biologic therapies. Fact.MR identifies biosimilar switching frameworks as a +0.6% CAGR opportunity, particularly in markets where physician oversight and reimbursement structures support switching.

Subcutaneous and self-administration formats represent another opportunity, with an estimated +0.8% impact on CAGR. These formats can reduce infusion-related burdens for selected maintenance patients and shift portions of care toward specialty pharmacies or home settings.

“Evidence quality and access support decide whether therapies move from approval into sustained use,” said Shambhu Nath Jha, Principal Consultant at Fact.MR. The commercial environment increasingly requires manufacturers to support clinical evidence with practical access and patient-management programs.

Hospitals Remain the Primary Care Setting

Hospitals are anticipated to account for 39.0% of the market in 2026, making them the leading end-user category.

Complex autoimmune therapies can require infusion capacity, laboratory screening, safety monitoring, and multidisciplinary assessment. Hospitals therefore remain important even as specialty clinics, ambulatory centers, and home healthcare expand their roles.

Hospital pharmacies are projected to hold 42.0% of distribution-channel share in 2026. Institutional dispensing fits monitored treatment workflows, particularly where therapy initiation or continuation depends on documented safety assessments.

For manufacturers, this means market access extends beyond regulatory approval. Formulary placement, reimbursement evidence, patient support, administration options, and continuation criteria can influence the commercial trajectory of a therapy.

Lupus and Sjögren's Disease Create Expansion Opportunities

Systemic lupus erythematosus and Sjögren's disease represent important areas for future market expansion.

The Fact.MR report identifies indication expansion in lupus and Sjögren disease as a +0.4% CAGR opportunity. In January 2026, Novartis announced that ianalumab received FDA Breakthrough Therapy designation for Sjögren's disease, illustrating continued industry interest in targeted treatment approaches for autoimmune conditions beyond rheumatoid arthritis.

Lupus treatment is also receiving continued regulatory and clinical attention. The FDA notes that lupus can affect multiple organs and that treatment goals include controlling symptoms, preventing flares, and reducing damage to joints and organs.

This creates a broader development opportunity for companies able to demonstrate disease-specific efficacy while managing safety, reimbursement, and long-term treatment requirements.

Germany Leads Country Growth

Germany is projected to record the fastest country-level growth at 5.9% CAGR from 2026 to 2036.

The market is expected to benefit from specialist prescribing and greater consideration of biosimilar treatment options. Brazil follows at 5.6% CAGR, supported by protocol-led access and institutional purchasing.

Canada is projected to grow at 5.3% CAGR, while the United States is expected to expand at 5.0% CAGR through broad therapy choice and specialty-channel management.

Australia is forecast to record 4.7% CAGR, followed by the United Kingdom at 4.3%. Japan is projected to grow at 3.8% CAGR, reflecting a more regulated review and post-approval adoption pathway.

Competitive Landscape

The competitive landscape includes F. Hoffmann-La Roche Ltd., Pfizer, Johnson & Johnson, AbbVie, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AstraZeneca, Amgen, and Sanofi.

Competition is increasingly shaped by mechanism-specific therapies, clinical evidence, administration routes, biosimilar strategies, reimbursement positioning, and patient-support programs. Fact.MR expects evidence quality and reimbursement fit to remain important competitive factors through 2036.

For pharmaceutical companies, the commercial opportunity extends beyond developing another autoimmune therapy. Products that simplify administration, support adherence, demonstrate disease-specific outcomes, and fit established specialist workflows may gain stronger adoption.

Connective Tissue Disease Market Snapshot

2025 market value: USD 28.4 billion
2026 market value: USD 29.8 billion
2036 projected value: USD 48.5 billion
CAGR, 2026–2036: 5.0%
Absolute opportunity: USD 18.7 billion
Leading disease type: Rheumatoid Arthritis, 36.0%
Leading treatment type: Biologics, 34.0%
Leading end user: Hospitals, 39.0%
Leading distribution channel: Hospital Pharmacies, 42.0%
Highest listed country CAGR: Germany, 5.9%
Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/connective-tissue-disease-market

Report Scope and Methodology

The Fact.MR study evaluates prescription therapy revenue for connective tissue diseases across defined disease, treatment, end-user, distribution, and drug-class categories. The scope includes rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, and mixed connective tissue disease.

Treatment categories include biologics, disease-modifying antirheumatic drugs, corticosteroids, immunosuppressants, and NSAIDs. Drug classes include monoclonal antibodies, JAK inhibitors, conventional synthetic drugs, immunomodulators, and biosimilars. Diagnostics, surgery, rehabilitation services, devices, and general wellness products are excluded.

Fact.MR states that its analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews. Market estimates combine treated populations, therapy mix, dosing, net sales, channel allocation, reimbursement conditions, safety review, adoption patterns, and company portfolios using a hybrid top-down and bottom-up approach.

Explore More Related Studies Published by Fact.MR Research

Health Economics and Outcomes Research Services Market- https://www.factmr.com/report/health-economics-and-outcomes-research-services-market

Healthcare Agentic Artificial Intelligence Market- https://www.factmr.com/report/healthcare-agentic-artificial-intelligence-market

Healthcare AI Consulting Services Market- https://www.factmr.com/report/healthcare-ai-consulting-services-market

Healthcare and Medical Devices Testing Inspection and Certification Market- https://www.factmr.com/report/healthcare-and-medical-devices-testing-inspection-and-certification-market

Healthcare Computerized Maintenance Management System Market- https://www.factmr.com/report/healthcare-computerized-maintenance-management-system-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, providing market intelligence and syndicated research across healthcare, food and beverage, consumer goods, technology, industrial goods, and other sectors. The company operates from offices in Rockville, Maryland, United States, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.